CARIS LIFE SCIENCES Business Summary

Caris Life Sciences Inc. (CAI) operates as a leading AI-driven TechBio company specializing in precision medicine and comprehensive molecular profiling. The company generates revenue through two primary segments: Molecular Profiling services, which utilize whole exome and whole transcriptome sequencing to guide clinical therapy selection, and Pharma Research and Developmental services, which leverage its vast clinico-genomic database for drug discovery and clinical trial optimization. In 2025, the company reported approximately $800 million in total revenue, with molecular profiling accounting for over 94% of its top-line growth. Caris competes directly with Guardant Health, Foundation Medicine (Roche), and Tempus AI, distinguishing itself through its multi-modal AI platform and a massive repository of real-world data that offers higher-resolution biological insights than traditional panel-based testing. The company was founded by Chairman and CEO David Dean Halbert, a veteran entrepreneur who previously built AdvancePCS into a Fortune 250 company before its $7.5 billion sale to Caremark. The executive leadership team includes President David Spetzler, PhD, Chief Technology Officer Valeriy Domenyuk, PhD, and Chief Medical Officer George W. Sledge, Jr., MD, a renowned oncologist. Caris is backed by a prestigious roster of institutional investors, including Sixth Street, T. Rowe Price, Silver Lake, and Fidelity Investments. Its Board of Directors features notable industry figures such as Lloyd B. Minor, MD (Dean of Stanford University School of Medicine), and Dave Fredrickson (EVP at AstraZeneca), reflecting a high degree of clinical and commercial pedigree that supports its position as a public leader in the precision oncology market.